AMCP Market Insights: Exploring Opportunities to Improve the Quality of Life for Those with Amyotrophic Lateral Sclerosis (ALS)
Join us on Wednesday, June 14th at 2:00 pm ET for a discussion on key observations from AMCP’s Market Insights Roundtable on Exploring Opportunities to Improve the Quality of Life for Those with Amyotrophic Lateral Sclerosis (ALS). Speakers will provide an overview of the current and evolving treatment landscape for ALS.
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive, and fatal neurodegenerative disease characterized by loss of motor neurons in the brain and spinal cord. Current treatments for ALS are largely focused on supportive care. Typically, treatment includes a combination of therapies along with durable medical equipment (DME) to help preserve quality of life as long as possible. Speakers will share insights from the roundtable on the patient journey, current access barriers and what one health plan has done to minimize those barriers.
Meeting Objectives:
- Review the current and evolving treatment landscape for Amyotrophic Lateral Sclerosis (ALS)
- Discuss the differences between the clinical trial environment and real-life experience
- Gain understanding of the patient journey and corresponding burden
- Look at the decision-making process and how collaboration between stakeholders can minimize access to care barriers
Speakers/Panelists:
Ryan Haumschild
Director of Pharmacy
Emory Healthcare and Winship Cancer Institute
Ryan Bitton
Senior Director, Pharmacy Services
Health Plan of Nevada, a UnitedHealthcare company
